학술논문
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Document Type
Article
Author
Gregorc, Vanesa; Novello, Silvia; Lazzari, Chiara; Barni, Sandro; Aieta, Michele; Mencoboni, Manlio; Grossi, Francesco; Pas, Tommaso De; de Marinis, Filippo; Bearz, Alessandra; Floriani, Irene; Torri, Valter; Bulotta, Alessandra; Cattaneo, Angela; Grigorieva, Julia; Tsypin, Maxim; Roder, Joanna; Doglioni, Claudio; Levra, Matteo Giaj; Petrelli, Fausto; Foti, Silvia; Viganò, Mariagrazia; Bachi, Angela; Roder, Heinrich
Source
In The Lancet Oncology June 2014 15(7):713-721
Subject
Language
ISSN
1470-2045